1. A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control
- Author
-
Bruce L. Innis, Riju Ray, Philip O. Buck, Rafik Bekkat-Berkani, Gonçalo Matias, Carine Claeys, and Gael Dos Santos
- Subjects
0301 basic medicine ,030106 microbiology ,Immunology ,Review ,Virus ,Quadrivalent Influenza Vaccine ,Seasonal influenza ,03 medical and health sciences ,0302 clinical medicine ,Antigen ,Influenza, Human ,Humans ,Immunology and Allergy ,Live attenuated influenza vaccine ,Medicine ,030212 general & internal medicine ,influenza B ,Disease burden ,Pharmacology ,quadrivalent influenza vaccine ,business.industry ,virus diseases ,Virology ,Influenza B virus ,Influenza Vaccines ,Human mortality from H5N1 ,influenza ,business ,mismatch - Abstract
The contribution of influenza B to the seasonal influenza burden varies from year-to-year. Although 2 antigenically distinct influenza B virus lineages have co-circulated since 2001, trivalent influenza vaccines (TIVs) contain antigens from only one influenza B virus. B-mismatch or co-circulation of both B lineages results in increased morbidity and mortality attributable to the B lineage absent from the vaccine. Quadrivalent vaccines (QIVs) contain both influenza B lineages. We reviewed currently licensed QIVs and their value by focusing on the preventable disease burden. Modeling studies support that QIVs are expected to prevent more influenza cases, hospitalisations and deaths than TIVs, although estimates of the case numbers prevented vary according to local specificities. The value of QIVs is demonstrated by their capacity to broaden the immune response and reduce the likelihood of a B-mismatched season. Some health authorities have preferentially recommended QIVs over TIVs in their influenza prevention programmes.
- Published
- 2017
- Full Text
- View/download PDF